

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BeiGene

BeiGene, Ltd.

百濟神州有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 06160)

CLARIFICATION ANNOUNCEMENT BEIGENE'S STATEMENT ON SHORT SELLER REPORT

This announcement is made by BeiGene, Ltd. ("**BeiGene**") (NASDAQ: BGNE; HKEX: 06160) on a voluntary basis.

On 5 September 2019, a report from a self-proclaimed short seller made numerous inaccurate, unfounded and misleading allegations about BeiGene designed to negatively impact BeiGene's share price for the short seller's own benefit. The allegations in the report are blatantly false.

From its inception, BeiGene has operated with an unwavering commitment to compliance, ethics, and integrity. BeiGene remains focused on its mission to build a biopharmaceutical company that will provide the highest quality therapies to the greatest number of patients around the world.

BeiGene also confirms that BeiGene does not currently possess any inside information that is required to be published pursuant to Rule 13.09 of the Rules Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited and under Part XIVA of the Securities and Futures Ordinance (Cap. 571).

About BeiGene

BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 2,700 employees in China, the United States, Australia and Europe, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin-bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.¹

By order of the Board
BeiGene, Ltd.
Mr. John V. Oyler
Chairman

Hong Kong, 6 September 2019

As at the date of this announcement, the Board of Directors of the Company comprises Mr. John V. Oyler as Chairman and Executive Director, Dr. Xiaodong Wang as Non-executive Director, and Mr. Timothy Chen, Mr. Donald W. Glazer, Mr. Michael Goller, Mr. Ranjeev Krishana, Mr. Thomas Malley, Mr. Jing-Shyh (Sam) Su and Mr. Qingqing Yi as Independent Non-executive Directors.

1. ABRAXANE®, REVLIMID® and VIDAZA® are registered trademarks of Celgene Corporation.